Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Asahi Kasei to Divest Medical Devices Unit to Integral, but Retains Bioprocess Biz
Japanese chemical conglomerate Asahi Kasei said on September 18 that it will sell Asahi Kasei Medical, a medical devices unit handling blood purification and other businesses, to Tokyo-based private equity fund Integral for 56.5 billion yen. Under the deal, 80%…
To read the full story
Related Article
- Asahi Kasei to Buy German Antiviral Specialist Aicuris for 143.1 Billion Yen
February 27, 2026
- Asahi Kasei Sees Tarpeyo Uptake Outpacing Forecast, Peak Sales Can Be Higher
January 9, 2026
- Asahi Kasei Pharma Confident of Hitting FY2030 Group Sales Target: President
December 10, 2025
- Asahi Kasei Sharpens Acquisition Focus in Pharma Biz as Envarsus LOE Looms
July 15, 2025
- Asahi Kasei on Hunt for M&A and Licensing Deals to Bolster Pharma Biz
April 15, 2025
- Asahi Kasei to Divest Diagnostics Biz to Nagase in July 2025
September 27, 2024
- Asahi Kasei Pivots toward Drug Business in Healthcare to Drive Growth
September 19, 2024
BUSINESS
- Ono Sets Course for Growth Beyond Opdivo Patent Cliff
March 25, 2026
- Fuji, Richter Strike Co-Development Pact in Women’s Health
March 25, 2026
- ASKA Inks AI Target Discovery Pact with Insilico in Women’s Health
March 25, 2026
- Shionogi to Fully Acquire Sleep Disorder JV SASS
March 25, 2026
- Stella Pharma Files Steboronine for Angiosarcoma
March 25, 2026
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…